Revolutionizing Lung Cancer Treatment Through FDA- Approved BCS Class II and Class IV Drug Nanoparticles

Lung carcinoma has been identified as leading causes of death due to cancer globally. However, there are currently novel therapies for lung cancer that might alter this fatality rate. Encorafenib and Binimetinib combined were authorized by the FDA on October 11, 2023, for people suffering from non-small cell lung cancer (NSCLC) and also have a BRAF V600E mutation. Both Lorlatinib and Dacomitinib, approved by FDA as a second-line therapy for non-small cell lung cancer in adults and adolescents aged 12 and above, were promptly cleared by the FDA on August 15, 2019. Due to their limited solubility, the majority of anticancer medications in BCS categories II and IV have inadequate bioavailability. To address this issue, for these drugs, we will create nanoparticles using a variety of nanoparticle production processes. The solid-state particles' disintegration and transit rate across the aqueous boundary layer and mucous barrier are increased by decreasing their size. Several drugs and targeted agents can be integrated into nanostructures (NPs), which improves gastrointestinal absorption, solubility, sustained administration, and bioavailability.